You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGolimumab
Accession NumberDB06674
TypeBiotech
GroupsApproved
DescriptionGolimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Protein structureDb06674
Related Articles
Protein chemical formulaC6530H10068N1752O2026S44
Protein average weight146943.1937 Da
SequencesNot Available
SynonymsNot Available
External IDs CNTO 148 / CNTO-148
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SimponiInjection, solution50 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiInjection, solution100 mg/mLSubcutaneousJanssen Biotech, Inc.2013-05-15Not applicableUs
SimponiSolution50 mgSubcutaneousJanssen Pharmaceuticals2009-06-22Not applicableCanada
SimponiInjection, solution50 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiSolution50 mgSubcutaneousJanssen Pharmaceuticals2009-06-22Not applicableCanada
SimponiInjection, solution50 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiSolution100 mgSubcutaneousJanssen Pharmaceuticals2013-10-03Not applicableCanada
SimponiInjection, solution100 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiInjection, solution100 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiInjection, solution100 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiInjection, solution100 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiSolution100 mgSubcutaneousJanssen Pharmaceuticals2013-10-03Not applicableCanada
SimponiInjection, solution50 mgSubcutaneousJanssen Biologics B.V.  2009-10-01Not applicableEu
SimponiInjection, solution50 mg/.5mLSubcutaneousJanssen Biotech, Inc.2009-04-25Not applicableUs
Simponi AriaSolution50 mg/4mLIntravenousJanssen Biotech, Inc.2013-07-19Not applicableUs
Simponi I.V.Solution50 mgIntravenousJanssen Pharmaceuticals2013-12-12Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII91X1KLU43E
CAS number476181-74-5
Pharmacology
IndicationUsed in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Structured Indications
PharmacodynamicsGolimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFα). In areas such as the joints and blood, increased TNFα is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of actionAs a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tumor necrosis factorProteinyes
antibody
HumanP01375 details
Related Articles
AbsorptionAfter subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 ± 1.4 μg/mL.
Volume of distribution

After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.

Protein bindingPlasma protein binding was not quantified.
Metabolism

The metabolism of golimumab has yet to be determined.

Route of eliminationThe route of elimination for golimumab has yet to be determined.
Half lifeGolimumab has a long half-life of about 2 weeks.
Clearance

After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.

ToxicityThe FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of adverse effects can be increased when Golimumab is combined with Abatacept.Approved
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Golimumab.Approved
AnakinraThe risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Canakinumab.Approved, Investigational
Certolizumab pegolGolimumab may increase the immunosuppressive activities of Certolizumab pegol.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Golimumab.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.Approved, Investigational
FingolimodGolimumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Golimumab is combined with G17DT.Investigational
InfliximabGolimumab may increase the immunosuppressive activities of Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Golimumab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Golimumab is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Golimumab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Golimumab.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Golimumab is combined with Rilonacept.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Golimumab is combined with CDX-110.Investigational
RituximabThe risk or severity of adverse effects can be increased when Golimumab is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Golimumab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Golimumab.Approved
SRP 299The risk or severity of adverse effects can be increased when Golimumab is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Golimumab.Approved, Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Golimumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Golimumab is combined with Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Golimumab.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Vedolizumab.Approved
Food Interactions
  • Since golimumab is administered by subcutaneous injection, there are no food effects.
References
Synthesis Reference

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 Mar;47(3):383-96.

General References
  1. Oldfield V, Plosker GL: Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005. [PubMed:19489653 ]
  2. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Rutgeerts P: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14. [PubMed:23770005 ]
External Links
ATC CodesL04AB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (1.9 MB)
MSDSDownload (567 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentUlcerative Colitis (UC)1
1CompletedTreatmentHealthy Adult Chinese Males1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentRheumatoid Arthritis1
1, 2TerminatedTreatmentAutoimmune Inner Ear Disease1
2CompletedTreatmentAsthma1
2CompletedTreatmentRheumatoid Arthritis2
2CompletedTreatmentSarcoidosis1
2CompletedTreatmentUlcerative Colitis (UC)1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentDiabetes Mellitus, Type 11
2TerminatedTreatmentRheumatoid Arthritis1
2, 3CompletedTreatmentUlcerative Colitis (UC)1
2, 3TerminatedTreatmentUlcerative Colitis (UC)1
3CompletedTreatmentAnkylosing Spondylitis (AS)4
3CompletedTreatmentArthritis / Autoimmune Diseases / Rheumatoid Arthritis1
3CompletedTreatmentPsoriatic Arthritis2
3CompletedTreatmentRheumatoid Arthritis8
3CompletedTreatmentUlcerative Colitis (UC)2
3RecruitingTreatmentJuvenile Idiopathic Arthritis (JIA)1
3RecruitingTreatmentPsoriatic Arthritis2
3RecruitingTreatmentSpondyloarthritis, Axial2
3TerminatedTreatmentJuvenile Idiopathic Arthritis (JIA)1
3TerminatedTreatmentRheumatoid Arthritis1
3Unknown StatusTreatmentPeripheral Spondylarthritis1
4CompletedTreatmentAnkylosing Spondylitis (AS)2
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSpondyloarthropathies1
4CompletedTreatmentUlcerative Colitis (UC)1
4Not Yet RecruitingTreatmentRheumatoid Arthritis1
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)2
4RecruitingDiagnosticUlcerative Colitis (UC)1
4RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentColitis1
4RecruitingTreatmentRheumatoid Arthritis2
4RecruitingTreatmentUlcerative Colitis (UC)1
4TerminatedNot AvailableRheumatoid Arthritis1
4Unknown StatusDiagnosticUlcerative Colitis (UC)1
4WithdrawnNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableActive Not RecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableSpondyloarthritis / Ultrasonography1
Not AvailableRecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableRecruitingNot AvailablePsoriatic Arthritis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis3
Not AvailableRecruitingNot AvailableUlcerative Colitis (UC)1
Not AvailableTerminatedNot AvailableRheumatoid Arthritis1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous100 mg/mL
Injection, solutionSubcutaneous100 mg
Injection, solutionSubcutaneous50 mg/.5mL
Injection, solutionSubcutaneous50 mg
SolutionSubcutaneous100 mg
SolutionSubcutaneous50 mg
SolutionIntravenous50 mg/4mL
SolutionIntravenous50 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Mittal M, Raychaudhuri SP: Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block. Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):602-8; quiz 609. doi: 10.4103/0378-6323.72445. [PubMed:21079302 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:47 / Updated on October 25, 2016 11:13